TY - JOUR
T1 - High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses
AU - Kratochvil, Christopher J.
AU - Michelson, David
AU - Newcorn, Jeffrey H.
AU - Weiss, Margaret D.
AU - Busner, Joan
AU - Moore, Rodney J.
AU - Ruff, Dustin D.
AU - Ramsey, Janet
AU - Dickson, Ruth
AU - Turgay, Atilla
AU - Saylor, Keith E.
AU - Luber, Stephen
AU - Vaughan, Brigette
AU - Allen, Albert J.
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2007/9
Y1 - 2007/9
N2 - OBJECTIVE: To assess the utility and tolerability of higher than standard atomoxetine doses to treat attention-deficit/hyperactivity disorder (ADHD). METHOD: Two randomized, double-blind trials of atomoxetine nonresponders ages 6 to 16 years were conducted comparing continued treatment with same-dose atomoxetine to treatment using greater than standard efficacious doses (study 1: up to 3.0 mg • kg • day; study 2: up to 2.4 mg • kg • day). RESULTS: The primary outcome measure for both studies was mean ADHD Rating Scale (ADHD RS) total score. For study 1 (N = 122), decreases in ADHD RS total scores were not significantly different between treatment groups (mean change [SD]: continued same dose, -8.9 [11.2]; high dose, -9.8 [13.1]; p = .595). Likewise, for study 2 (N = 125), treatment groups did not differ (mean change [SD]: continued same dose, -6.2 [12.2]; high dose, -8.9 [10.0], p =.110). Tolerability was not significantly different between the continued same-dose and high-dose groups. CONCLUSIONS: These studies provide evidence that current dose recommendations are appropriate for most patients, suggesting no systematic advantage to increasing atomoxetine doses beyond current guidelines. In both studies, continued treatment, whether at a higher dose or the previous dose, was associated with improved outcomes in patients who demonstrated incomplete/inadequate response to acute ADHD treatment, although without a placebo arm, we cannot rule out the possibility that expectancy played a role in symptom improvement. Copyright 2007
AB - OBJECTIVE: To assess the utility and tolerability of higher than standard atomoxetine doses to treat attention-deficit/hyperactivity disorder (ADHD). METHOD: Two randomized, double-blind trials of atomoxetine nonresponders ages 6 to 16 years were conducted comparing continued treatment with same-dose atomoxetine to treatment using greater than standard efficacious doses (study 1: up to 3.0 mg • kg • day; study 2: up to 2.4 mg • kg • day). RESULTS: The primary outcome measure for both studies was mean ADHD Rating Scale (ADHD RS) total score. For study 1 (N = 122), decreases in ADHD RS total scores were not significantly different between treatment groups (mean change [SD]: continued same dose, -8.9 [11.2]; high dose, -9.8 [13.1]; p = .595). Likewise, for study 2 (N = 125), treatment groups did not differ (mean change [SD]: continued same dose, -6.2 [12.2]; high dose, -8.9 [10.0], p =.110). Tolerability was not significantly different between the continued same-dose and high-dose groups. CONCLUSIONS: These studies provide evidence that current dose recommendations are appropriate for most patients, suggesting no systematic advantage to increasing atomoxetine doses beyond current guidelines. In both studies, continued treatment, whether at a higher dose or the previous dose, was associated with improved outcomes in patients who demonstrated incomplete/inadequate response to acute ADHD treatment, although without a placebo arm, we cannot rule out the possibility that expectancy played a role in symptom improvement. Copyright 2007
KW - Atomoxetine
KW - Attention-deficit/hyperactivity disorder
KW - Dose
UR - http://www.scopus.com/inward/record.url?scp=34548071916&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548071916&partnerID=8YFLogxK
U2 - 10.1097/chi.0b013e318074eeb3
DO - 10.1097/chi.0b013e318074eeb3
M3 - Article
C2 - 17712236
AN - SCOPUS:34548071916
SN - 0890-8567
VL - 46
SP - 1128
EP - 1137
JO - Journal of the American Academy of Child and Adolescent Psychiatry
JF - Journal of the American Academy of Child and Adolescent Psychiatry
IS - 9
ER -